InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,973.22
(
0.84%
)
Post# of 253346
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: DewDiligence post# 52787

Monday, 09/24/2007 2:50:56 PM

Monday, September 24, 2007 2:50:56 PM

Post# of 253346
Selling a premium-priced drug to hospitals is a tough business to be in because hospitals are smart and poor (or think they are).

I believed this to be true, also, which is why I never thought Abraxane would sell. Turns out this is wrong. The interesting thing about Abraxane sales is they are heavily concentrated in hospitals.

We believed it wouldn't sell well in community oncology practices because of the pharmacist overhead required to construct the drug. This turned out to be right, at least so far.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up